• 首页期刊简介编委会刊物订阅专栏专刊电子刊学术动态联系我们English
引用本文:丁凯,魏筱华,杨慧,凯散尔·热西提,陈旭,焦守峰,程周洋.血液肿瘤继发侵袭性真菌感染患者的伏立康唑群体药动学研究[J].中国现代应用药学,2026,43(19):106-114.
dingkai,weixiaohua,yanghui,kaisaer,chenxu,jiaoshoufeng,chengzhouyang.Population Pharmacokinetics of Voriconazole in Hematological Malignancy Patients with Invasive Fungal Infections[J].Chin J Mod Appl Pharm(中国现代应用药学),2026,43(19):106-114.
【打印本页】   【HTML】   【下载PDF全文】   【查看/发表评论】  【EndNote】   【RefMan】   【BibTex】
←前一篇|后一篇→ 过刊浏览    高级检索
本文已被:浏览 24次   下载 7次 本文二维码信息
码上扫一扫!
血液肿瘤继发侵袭性真菌感染患者的伏立康唑群体药动学研究
丁凯1, 魏筱华2, 杨慧3, 凯散尔·热西提4, 陈旭4, 焦守峰2, 程周洋4
1.九江市第一人民医院,九江市细胞治疗重点实验室,药剂科;2.南昌大学第一附属医院;3.九江市第三人民医院;4.南昌大学药学院
摘要:
目的 探讨能显著影响伏立康唑在血液恶性肿瘤患者继发侵袭性真菌感染患者中的群体药动学因素,进一步研究个体化给药最佳方案。方法 回顾性收集南昌大学第一附属医院血液科在2021年1月至2024年10月期间收治的80例血液恶性肿瘤合并继发侵袭性真菌感染患者的135例次伏立康唑血药谷浓度监测数据,使用非线性混合效应模型(NONMEM)进行建模和数据分析,并纳入协变量,经内部验证(自举法、可视化预测检验等)与独立的外部验证模型的稳定性和预测能力后,确立最终模型。结果 为血液肿瘤继发侵袭性真菌感染患者建立了静脉内给药的一房室统计学模型, 最终模型的群体药代动力学参数清除率(CL)为2.61L/h,分布体积(V)为100.07L。观察到rs10912675和丙氨酸氨基转移酶(ALT)能够显著影响表观分布容积(V),白细胞计数(WBC)能显著影响表观清除率(CL)。结论 最终模型具有良好的稳定性和预测性能,证实了rs10912675、ALT和WBC是导致伏立康唑药动学变异的主要因素。rs10912675、丙氨酸氨基转移酶(ALT)和白细胞计数(WBC)可导致伏立康唑药代动力学变化,在血液肿瘤继发侵袭性真菌感染患者中,狭窄的治疗指数和病理生理异质性需要制定个体化给药方案。
关键词:  血液肿瘤,侵袭性真菌感染,伏立康唑,群体药代动力学,血药浓度监测
DOI:
分类号:
基金项目:江西省科学技术厅重点研发计划项目
Population Pharmacokinetics of Voriconazole in Hematological Malignancy Patients with Invasive Fungal Infections
dingkai,weixiaohua,yanghui,kaisaer,chenxu,jiaoshoufeng,chengzhouyang
1.JiuJiang City Key Laboratory of Cell Therapy,JiuJiang NO.1 People’s Hospital;2.The First Affiliated Hospital Of NanChang University
Abstract:
Abstract: Objective To investigate the population pharmacokinetic factors significantly influencing voriconazole in hematologic malignancy patients with invasive fungal infections, and to optimize individualized dosing regimens.Methods A population pharmacokinetic model of voriconazole was developed using 135 trough concentrations retrospectively collected from 80 patients with hematologic malignancies and invasive fungal infections. The model, developed using NONMEM and incorporating key covariates, was validated internally (e.g., bootstrapping, visual predictive checks) and externally, confirming its stability and predictive performance.Results The developed population pharmacokinetic model for intravenous voriconazole yielded a clearance (CL) of 2.61 L/h and a volume of distribution (V) of 100.07 L. The covariate analysis revealed that the apparent volume of distribution (V) was significantly influenced by rs10912675 and alanine aminotransferase (ALT), while the white blood cell (WBC) count significantly affected the apparent clearance (CL).Conclusions The validated model confirmed rs10912675, ALT, and WBC as critical factors driving voriconazole pharmacokinetic variability. Individualized dosing is, therefore, essential to optimize therapy in this heterogeneous patient population, considering voriconazole's narrow therapeutic index
Key words:  hematologic neoplasms, invasive fungal Infections, voriconazole, population pharmacokinetics, blood concentration monitoring
扫一扫关注本刊微信